Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02663908 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
NCT02663908: Clinical Trial Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT02663908 is a Phase 3 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 545 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02663908, a Phase 3 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
Study Summary
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.
Primary Outcome
Composite MACE endpoint was defined as: death due to any cause, non-fatal myocardial infarction or non-fatal stroke. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict first confirmed (adjudicated) occurrence of composite MACE over time. Percentage of observed subjects with outcome measure events during the trial are reported. Subjects were censored at the time a subject discontinued the trial, was lost to follow-up, discontinued treatment with IMP, ini
Interventions
- DRUG Degarelix
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2016-04-19 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 3 |
Why NCT02663908 stopped before completion
NCT02663908 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT02663908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02663908 about?
NCT02663908 is a clinical study titled "A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease". The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.
What is the current status of trial NCT02663908?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2016-04-19. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT02663908?
The interventions under investigation include: Degarelix (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT02663908?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02663908's enrollment target sits among peer trials
545 689th of 2000 higher than 1,310 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI